| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Bioymifi is an DR5 activator (Kd = 1.2 µM; IC50 = 2 µM). Independent of TRAIL, Bioymifi triggers apoptosis through the TRAIL-related apoptosis-inducing ligand (DR5) death receptor. Apoptosis can be brought on by Bioymifi acting as a single agent to cause DR5 clustering and aggregation. The death receptors DR4 and DR5 are used by the substance tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) to activate apoptosis.
| Targets |
DR5 receptor (Kd = 1.2 μM)
|
|---|---|
| ln Vitro |
In T98G cells, Bioymifi can induce cell death without the assistance of the Smac mimetic. Bioymifi induces the processing of caspase-3 into smaller fragments at a concentration of 10 μM. For bioymifi-induced cell death to occur, caspase-8 and the associated extrinsic apoptotic pathway are necessary. DR5-dependent death pathways are induced by Bioymifi, wholly unaffected by TRAIL. With a Kd of 1.2 μM, Bioymifi binds the DR5 ECD but has low affinity for the DR4 ECD. In buffer solutions, it is not very soluble. By interacting with and facilitating the aggregation of DR5, Bioymifi aids in the promotion of apoptosis. The ability of bioymifi to aggregate DR5 at micromolar concentrations is potent enough to cause apoptosis in a variety of cancer cells[1].
|
| Cell Assay |
Plotted as a function of A2C2 or bioymifi concentration are the dose-response curves for bioymifi and A2C2 in T98G cells. A2C2 or bioymifi, alone or in combination with 1 μM Smac mimetic (SM), are applied to human glioblastoma (T98G) cells in a range of concentrations for 48 hours. A2C2 or bioymifi-free treatment is used to normalize the corresponding cell survival.
|
| References |
| Molecular Formula |
C22H12BRN3O4S
|
|---|---|
| Molecular Weight |
494.319
|
| Exact Mass |
492.97
|
| Elemental Analysis |
C, 53.46; H, 2.45; Br, 16.16; N, 8.50; O, 12.95; S, 6.49
|
| CAS # |
1420071-30-2
|
| Related CAS # |
1420071-30-2
|
| Appearance |
Solid powder
|
| SMILES |
C1=CC(=CC=C1N2C(=O)/C(=C/C3=CC=C(O3)C4=CC5=C(C=C4)C(=O)NC5=O)/SC2=N)Br
|
| InChi Key |
ULBOWKXOFOTCMU-NLDKGBHCSA-N
|
| InChi Code |
InChI=1S/C22H12BrN3O4S/c23-12-2-4-13(5-3-12)26-21(29)18(31-22(26)24)10-14-6-8-17(30-14)11-1-7-15-16(9-11)20(28)25-19(15)27/h1-10,24H,(H,25,27,28)/b18-10-,24-22?
|
| Chemical Name |
5-[5-[(Z)-[3-(4-bromophenyl)-2-imino-4-oxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]isoindole-1,3-dione
|
| Synonyms |
Bioymifi
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 12.5~43 mg/mL (25.3~9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (2.53 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 8.33 mg/mL (16.85 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0230 mL | 10.1149 mL | 20.2298 mL | |
| 5 mM | 0.4046 mL | 2.0230 mL | 4.0460 mL | |
| 10 mM | 0.2023 mL | 1.0115 mL | 2.0230 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA